No Data
No Data
Milestone Pharmaceuticals Bolsters Board With New Directors
Milestone Pharmaceuticals Appoints Two New Independent Directors, Stuart Duty and Andrew Saik >MIST
Milestone Pharmaceuticals Appoints Two New Independent Directors, Stuart Duty and Andrew Saik >
THE MILESTONE GROUP ANNOUNCES ACQUISITION OF AXIS DELRAY BEACH APARTMENTS IN DELRAY BEACH, FLORIDA
DELRAY BEACH, Fla., June 27, 2024 /PRNewswire/ -- The Milestone Group (Milestone) announces its acquisition of the Axis Delray Beach Apartments, a 488-unit, garden-style multifamily community located
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
TD Cowen analyst Ritu Baral maintains $Milestone Pharmaceuticals(MIST.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 45.7% a
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $5
Piper Sandler analyst Edward Tenthoff maintains $Milestone Pharmaceuticals(MIST.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate
Milestone Pharmaceuticals to Host KOL Event for Investors "Learnings From the Field: Expert Perspectives on PSVT in the Community Setting" on June 20, 2024
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat
No Data